Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls

被引:50
作者
Blann, AD [1 ]
Amiral, J
McCollum, CN
Lip, GYH
机构
[1] Univ Birmingham, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England
[2] Serbio Diagnost Stago, F-92635 Gennevilliers, France
[3] Univ S Manchester Hosp, Dept Surg, Manchester M20 8LR, Lancs, England
关键词
endothelium; peripheral vascular disease; tissue factor; tissue factor pathway inhibitor; von Willebrand factor;
D O I
10.1016/S0021-9150(99)00444-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tissue factor (TF) is one of the major initiators of coagulation and raised plasma levels have been found in various cardiovascular diseases. TF activity is, however, regulated by tissue factor pathway inhibitor (TFPI), and alteration in levels of TF and/or TFPI may thus relate to thrombogenesis and atherogenesis. To investigate possible abnormalities in TF and free TFPI (i.e. unbound to TF) and total TFPI among patients with peripheral artery disease (PAD), we studied 42 patients (mean age 57, 35 men) with objectively proven (by ABPI/Doppler) disease and 42 age- and sex- matched healthy controls. TF, free TFPI and total TFPI were measured in citrated plasma by ELISA. TF was higher in the patients with PAD compared to controls (275 +/- 122 pg/ml versus 158 +/- 60, P < 0.0001) but levels of total TFPI were lower in the patients (43 +/- 10 ng/ml versus 50 +/- 15, P = 0.021). There was no significant difference in levels of free TFPI between patients and controls (7.2 +/- 1.5 ng/ml in controls, 7.5 +/- 1.6 among patients, P = 0.39). Within the control patients, levels of free and total TFPI were significantly correlated (Spearman r = 0.51, P = 0.001) but in the patients with PAD this correlation was poor (r = 0.21, P = 0.178). We suggest that reduced levels of total TFPI and raised levels of TF may contribute to the process of atherogenesis and the increased risk of thrombosis among patients with cardiovascular disease. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 32 条
[1]  
Altman DG, 1990, PRACTICAL STAT MED R
[2]  
[Anonymous], 1997, Cardiovasc Res, V35, P2
[3]  
Ariëns RAS, 1999, THROMB HAEMOSTASIS, V81, P203
[4]  
Bajaj MS, 1997, THROMB HAEMOSTASIS, V78, P471
[5]   Von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia [J].
Blann, AD ;
Miller, JP ;
McCollum, CN .
ATHEROSCLEROSIS, 1997, 132 (02) :151-156
[6]   The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications [J].
Blann, AD ;
Yip, GYH .
BLOOD COAGULATION & FIBRINOLYSIS, 1998, 9 (04) :297-306
[7]  
Boffa MC, 1996, HAEMOSTASIS, V26, P233
[8]   Development of a method to separate lipoprotein-bound and lipoprotein-depleted tissue factor pathway inhibitor.: Measurement of free tissue factor pathway inhibitor activity [J].
Bridey, F ;
Lacombe, C ;
Sustendal, L ;
Moatti, D ;
Combe, F ;
Mammès, O ;
de Prost, D .
BLOOD COAGULATION & FIBRINOLYSIS, 1998, 9 (07) :637-643
[9]   Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity [J].
Caplice, NM ;
Mueske, CS ;
Kleppe, LS ;
Simari, RD .
CIRCULATION, 1998, 98 (11) :1051-1057
[10]   FUNCTIONAL TISSUE FACTOR IS ENTIRELY CELL-SURFACE EXPRESSED ON LIPOPOLYSACCHARIDE-STIMULATED HUMAN-BLOOD MONOCYTES AND A CONSTITUTIVELY TISSUE FACTOR PRODUCING NEOPLASTIC CELL-LINE [J].
DRAKE, TA ;
RUF, W ;
MORRISSEY, JH ;
EDGINGTON, TS .
JOURNAL OF CELL BIOLOGY, 1989, 109 (01) :389-395